{"success":true,"data":{"pressRelease":{"id":"91465","rtpr_id":"nPn51BQLta","ticker":"RGNX","exchange":"NASDAQ","all_tickers":["RGNX"],"title":"REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants","author":"PR Newswire","published_at":"2026-07-17T11:00:02.629Z","article_body":"REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants\n\nPR Newswire\n\nROCKVILLE, Md., July 17, 2026\n\nROCKVILLE, Md., July 17, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)\ntoday announced the pricing of an underwritten public offering of 10,003,889\nshares of its common stock at the price of $9.00 per share and 1,111,111\npre-funded warrants at a price of $8.9999 per warrant, in each case before\nunderwriting discounts and commissions. The gross proceeds to REGENXBIO from\nthe offering, before deducting the underwriting discounts and commissions and\nother offering expenses payable by REGENXBIO, are expected to be\napproximately $100.0 million. This offering is expected to close on July 20,\n2026, subject to customary closing conditions. In addition, REGENXBIO has\ngranted the underwriters a 30-day option to purchase an additional 1,667,250\nshares of common stock at the public offering price, less underwriting\ndiscounts and commissions.\n\nMorgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint\nbook-running managers of the offering.\n\nThe securities described above are being offered by REGENXBIO pursuant to a\nRegistration Statement on Form S-3 that was filed with the Securities and\nExchange Commission (the \"SEC\") on November 26, 2025 (File No. 333-291816) and\ndeclared effective on December 12, 2025. A preliminary prospectus supplement\nrelating to and describing the terms of the offering was filed with the SEC\nand is available on the SEC's website at www.sec.gov\n(file:///C:/Users/YanJ/Downloads/www.sec.gov) . Copies of the preliminary\nprospectus supplement and the accompanying prospectus relating to this\noffering, when available, may be obtained from: Morgan Stanley & Co. LLC,\nAttention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY\n10014, or by email at prospectus@morganstanley.com\n(mailto:prospectus@morganstanley.com) ; J.P. Morgan Securities LLC, c/o\nBroadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York\n11717 or by email at prospectus-eq_fi@jpmchase.com\n(mailto:prospectus-eq_fi@jpmchase.com) and\npostsalemanualrequests@broadridge.com\n(mailto:postsalemanualrequests@broadridge.com) ; Leerink Partners LLC,\nAttention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA\n02109, or by telephone at (800) 808-7525, ext. 6105, or by email at\nsyndicate@leerink.com (mailto:syndicate@leerink.com) ; Mizuho Securities USA\nLLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd\nFloor, New York, NY 10022, by telephone (212) 205-7600, or by email:\nUS-ECM@mizuhogroup.com (mailto:US-ECM@mizuhogroup.com) . The final terms of\nthe offering will be disclosed in a final prospectus supplement to be filed\nwith the SEC.\n\nThis press release shall not constitute an offer to sell or a solicitation of\nan offer to buy any of these securities, nor shall there be any sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation or\nsale would be unlawful prior to registration or qualification under the\napplicable securities laws of such state or jurisdiction.\n\nABOUT REGENXBIO Inc.\n\nREGENXBIO is a biotechnology company on a mission to improve lives through the\ncurative potential of gene therapy. Since its founding in 2009, REGENXBIO has\npioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage\npipeline of one-time treatments for rare and retinal diseases, including\nRGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314)\nfor the treatment of wet AMD and diabetic retinopathy, in collaboration with\nAbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the\ntreatment of MPS II and RGX-111 for the treatment of MPS I, both in\npartnership with Nippon Shinyaku. Thousands of patients have been treated with\nREGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA(®).\nREGENXBIO's investigational gene therapies have the potential to change the\nway healthcare is delivered for millions of people.\n\nFORWARD-LOOKING STATEMENTS\n\nThis press release includes \"forward-looking statements,\" within the meaning\nof Section 27A of the Securities Act of 1933, as amended, and Section 21E of\nthe Securities Exchange Act of 1934, as amended. These statements express a\nbelief, expectation or intention and are generally accompanied by words that\nconvey projected future events or outcomes such as \"anticipate,\" \"assume,\"\n\"believe,\" \"continue,\" \"could,\" \"design,\" \"estimate,\" \"expect,\" \"forecast,\"\n\"goal,\" \"intend,\" \"may,\" \"objective,\" \"plan,\" \"position,\" \"potential,\"\n\"predict,\" \"project,\" \"seek,\" \"should,\" \"will,\" \"would\" or variations of such\nwords or by similar expressions. The forward-looking statements include\nstatements relating to, among other things, statements regarding the timing\nand success of the proposed offering and whether REGENXBIO will be able to\nraise capital through the sale of shares of common stock. REGENXBIO has based\nthese forward-looking statements on its current expectations and assumptions\nand analyses made by REGENXBIO in light of its experience and its perception\nof historical trends, current conditions and expected future developments, as\nwell as other factors REGENXBIO believes are appropriate under the\ncircumstances. However, whether actual results and developments will conform\nwith REGENXBIO's expectations and predictions is subject to a number of risks\nand uncertainties, including the timing of enrollment, commencement and\ncompletion and the success of clinical trials conducted by REGENXBIO, its\nlicensees and its partners, the timing of commencement and completion and the\nsuccess of preclinical studies conducted by REGENXBIO and its development\npartners, the timely development and launch of new products, the ability to\nobtain and maintain regulatory approval of product candidates, the ability to\nobtain and maintain intellectual property protection for product candidates\nand technology, trends and challenges in the business and markets in which\nREGENXBIO operates, the size and growth of potential markets for product\ncandidates and the ability to serve those markets, the rate and degree of\nacceptance of product candidates, and other factors, many of which are beyond\nthe control of REGENXBIO. Refer to the \"Risk Factors\" and \"Management's\nDiscussion and Analysis of Financial Condition and Results of Operations\"\nsections of REGENXBIO's Annual Report on Form 10-K for the year ended December\n31, 2025, and comparable \"Risk Factors\" sections of REGENXBIO's Quarterly\nReports on Form 10-Q and other filings, which have been filed with the U.S.\nSecurities and Exchange Commission (the \"SEC\") and are available on the SEC's\nwebsite at www.sec.gov (http://www.sec.gov) . All of the forward-looking\nstatements made in this press release are expressly qualified by the\ncautionary statements contained or referred to herein. The actual results or\ndevelopments anticipated may not be realized or, even if substantially\nrealized, they may not have the expected consequences to or effects on\nREGENXBIO or its businesses or operations. Such statements are not guarantees\nof future performance and actual results or developments may differ materially\nfrom those projected in the forward-looking statements. Readers are cautioned\nnot to rely too heavily on the forward-looking statements contained in this\npress release. These forward-looking statements speak only as of the date of\nthis press release. Except as required by law, REGENXBIO does not undertake\nany obligation, and specifically declines any obligation, to update or revise\nany forward-looking statements, whether as a result of new information, future\nevents or otherwise.\n\nZOLGENSMA(®) is a registered trademark of Novartis. All other trademarks\nreferenced herein are registered trademarks of REGENXBIO.\n\nCONTACTS:\n\nDana Cormack\nCorporate Communications\nDcormack@regenxbio.com (mailto:Dcormack@regenxbio.com)\n\nInvestors:\nGeorge E. MacDougall\nInvestor Relations\nIR@regenxbio.com (mailto:IR@regenxbio.com)\n\n \n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants-302828273.html\n(https://www.prnewswire.com/news-releases/regenxbio-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants-302828273.html)\n\nSOURCE REGENXBIO Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1147952/RGNX-Logo.jpg?id=OA2768432\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn51BQLta","title":"REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants","author":"PR Newswire","ticker":"RGNX","created":"2026-07-17T11:00:02.629Z","tickers":["RGNX"],"exchange":"NASDAQ","article_body":"REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants\n\nPR Newswire\n\nROCKVILLE, Md., July 17, 2026\n\nROCKVILLE, Md., July 17, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)\ntoday announced the pricing of an underwritten public offering of 10,003,889\nshares of its common stock at the price of $9.00 per share and 1,111,111\npre-funded warrants at a price of $8.9999 per warrant, in each case before\nunderwriting discounts and commissions. The gross proceeds to REGENXBIO from\nthe offering, before deducting the underwriting discounts and commissions and\nother offering expenses payable by REGENXBIO, are expected to be\napproximately $100.0 million. This offering is expected to close on July 20,\n2026, subject to customary closing conditions. In addition, REGENXBIO has\ngranted the underwriters a 30-day option to purchase an additional 1,667,250\nshares of common stock at the public offering price, less underwriting\ndiscounts and commissions.\n\nMorgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint\nbook-running managers of the offering.\n\nThe securities described above are being offered by REGENXBIO pursuant to a\nRegistration Statement on Form S-3 that was filed with the Securities and\nExchange Commission (the \"SEC\") on November 26, 2025 (File No. 333-291816) and\ndeclared effective on December 12, 2025. A preliminary prospectus supplement\nrelating to and describing the terms of the offering was filed with the SEC\nand is available on the SEC's website at www.sec.gov\n(file:///C:/Users/YanJ/Downloads/www.sec.gov) . Copies of the preliminary\nprospectus supplement and the accompanying prospectus relating to this\noffering, when available, may be obtained from: Morgan Stanley & Co. LLC,\nAttention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY\n10014, or by email at prospectus@morganstanley.com\n(mailto:prospectus@morganstanley.com) ; J.P. Morgan Securities LLC, c/o\nBroadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York\n11717 or by email at prospectus-eq_fi@jpmchase.com\n(mailto:prospectus-eq_fi@jpmchase.com) and\npostsalemanualrequests@broadridge.com\n(mailto:postsalemanualrequests@broadridge.com) ; Leerink Partners LLC,\nAttention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA\n02109, or by telephone at (800) 808-7525, ext. 6105, or by email at\nsyndicate@leerink.com (mailto:syndicate@leerink.com) ; Mizuho Securities USA\nLLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd\nFloor, New York, NY 10022, by telephone (212) 205-7600, or by email:\nUS-ECM@mizuhogroup.com (mailto:US-ECM@mizuhogroup.com) . The final terms of\nthe offering will be disclosed in a final prospectus supplement to be filed\nwith the SEC.\n\nThis press release shall not constitute an offer to sell or a solicitation of\nan offer to buy any of these securities, nor shall there be any sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation or\nsale would be unlawful prior to registration or qualification under the\napplicable securities laws of such state or jurisdiction.\n\nABOUT REGENXBIO Inc.\n\nREGENXBIO is a biotechnology company on a mission to improve lives through the\ncurative potential of gene therapy. Since its founding in 2009, REGENXBIO has\npioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage\npipeline of one-time treatments for rare and retinal diseases, including\nRGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314)\nfor the treatment of wet AMD and diabetic retinopathy, in collaboration with\nAbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the\ntreatment of MPS II and RGX-111 for the treatment of MPS I, both in\npartnership with Nippon Shinyaku. Thousands of patients have been treated with\nREGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA(®).\nREGENXBIO's investigational gene therapies have the potential to change the\nway healthcare is delivered for millions of people.\n\nFORWARD-LOOKING STATEMENTS\n\nThis press release includes \"forward-looking statements,\" within the meaning\nof Section 27A of the Securities Act of 1933, as amended, and Section 21E of\nthe Securities Exchange Act of 1934, as amended. These statements express a\nbelief, expectation or intention and are generally accompanied by words that\nconvey projected future events or outcomes such as \"anticipate,\" \"assume,\"\n\"believe,\" \"continue,\" \"could,\" \"design,\" \"estimate,\" \"expect,\" \"forecast,\"\n\"goal,\" \"intend,\" \"may,\" \"objective,\" \"plan,\" \"position,\" \"potential,\"\n\"predict,\" \"project,\" \"seek,\" \"should,\" \"will,\" \"would\" or variations of such\nwords or by similar expressions. The forward-looking statements include\nstatements relating to, among other things, statements regarding the timing\nand success of the proposed offering and whether REGENXBIO will be able to\nraise capital through the sale of shares of common stock. REGENXBIO has based\nthese forward-looking statements on its current expectations and assumptions\nand analyses made by REGENXBIO in light of its experience and its perception\nof historical trends, current conditions and expected future developments, as\nwell as other factors REGENXBIO believes are appropriate under the\ncircumstances. However, whether actual results and developments will conform\nwith REGENXBIO's expectations and predictions is subject to a number of risks\nand uncertainties, including the timing of enrollment, commencement and\ncompletion and the success of clinical trials conducted by REGENXBIO, its\nlicensees and its partners, the timing of commencement and completion and the\nsuccess of preclinical studies conducted by REGENXBIO and its development\npartners, the timely development and launch of new products, the ability to\nobtain and maintain regulatory approval of product candidates, the ability to\nobtain and maintain intellectual property protection for product candidates\nand technology, trends and challenges in the business and markets in which\nREGENXBIO operates, the size and growth of potential markets for product\ncandidates and the ability to serve those markets, the rate and degree of\nacceptance of product candidates, and other factors, many of which are beyond\nthe control of REGENXBIO. Refer to the \"Risk Factors\" and \"Management's\nDiscussion and Analysis of Financial Condition and Results of Operations\"\nsections of REGENXBIO's Annual Report on Form 10-K for the year ended December\n31, 2025, and comparable \"Risk Factors\" sections of REGENXBIO's Quarterly\nReports on Form 10-Q and other filings, which have been filed with the U.S.\nSecurities and Exchange Commission (the \"SEC\") and are available on the SEC's\nwebsite at www.sec.gov (http://www.sec.gov) . All of the forward-looking\nstatements made in this press release are expressly qualified by the\ncautionary statements contained or referred to herein. The actual results or\ndevelopments anticipated may not be realized or, even if substantially\nrealized, they may not have the expected consequences to or effects on\nREGENXBIO or its businesses or operations. Such statements are not guarantees\nof future performance and actual results or developments may differ materially\nfrom those projected in the forward-looking statements. Readers are cautioned\nnot to rely too heavily on the forward-looking statements contained in this\npress release. These forward-looking statements speak only as of the date of\nthis press release. Except as required by law, REGENXBIO does not undertake\nany obligation, and specifically declines any obligation, to update or revise\nany forward-looking statements, whether as a result of new information, future\nevents or otherwise.\n\nZOLGENSMA(®) is a registered trademark of Novartis. All other trademarks\nreferenced herein are registered trademarks of REGENXBIO.\n\nCONTACTS:\n\nDana Cormack\nCorporate Communications\nDcormack@regenxbio.com (mailto:Dcormack@regenxbio.com)\n\nInvestors:\nGeorge E. MacDougall\nInvestor Relations\nIR@regenxbio.com (mailto:IR@regenxbio.com)\n\n \n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants-302828273.html\n(https://www.prnewswire.com/news-releases/regenxbio-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants-302828273.html)\n\nSOURCE REGENXBIO Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1147952/RGNX-Logo.jpg?id=OA2768432\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-07-17T11:00:03.077728357Z","server_sent_at_ms":1784286003077},"received_at":"2026-07-17T11:00:03.143Z","source_url":"https://www.prnewswire.com/news-releases/regenxbio-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants-302828273.html"},"analysis":{"id":"80513","press_release_id":"91465","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"REGENXBIO priced a public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant.\n\nThe offering is expected to generate approximately $100.0 million in gross proceeds before expenses, with a closing date set for July 20, 2026.\n\nMorgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-running managers, and underwriters have a 30-day option to purchase an additional 1,667,250 shares.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"REGENXBIO raises $100M in capital via public offering and pre-funded warrants."},"keyFigures":{"dealValueUsd":100000000,"offeringPrice":9,"sharesOffered":10003889,"customDimensions":{"warrant_price":8.9999,"greenshoe_shares":1667250,"pre_funded_warrants":1111111}},"quotedText":"","namedEntities":{"people":[{"name":"Dana Cormack","role":"Corporate Communications"},{"name":"George E. MacDougall","role":"Investor Relations"}],"products":["RGX-202","ABBV-RGX-314","NAVSUNLI","RGX-121","RGX-111","ZOLGENSMA"],"companies":[{"name":"REGENXBIO Inc.","ticker":"RGNX"},{"name":"Morgan Stanley","relationship":"underwriter"},{"name":"J.P. Morgan","relationship":"underwriter"},{"name":"Leerink Partners","relationship":"underwriter"},{"name":"Mizuho","relationship":"underwriter"},{"name":"AbbVie","relationship":"partner"},{"name":"Nippon Shinyaku","relationship":"partner"},{"name":"Novartis","relationship":"partner"}],"dollarAmounts":[{"amount":"$9.00","context":"public offering price per share"},{"amount":"$8.9999","context":"pre-funded warrant price"},{"amount":"$100.0 million","context":"expected gross proceeds"}]},"materialImpact":{"score":4,"reasoning":"The company is raising approximately $100 million in gross proceeds through a public offering of common stock and pre-funded warrants, resulting in significant shareholder dilution of over 11 million primary units."},"tickerRelevance":{"others":[],"primary":"RGNX"},"globalImportance":30,"audienceRelevance":25,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"equity_offering","sectorWeight":"biotech"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":4,"narrative":"REGENXBIO priced a public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant.\n\nThe offering is expected to generate approximately $100.0 million in gross proceeds before expenses, with a closing date set for July 20, 2026.\n\nMorgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-running managers, and underwriters have a 30-day option to purchase an additional 1,667,250 shares.","key_figures":{"dealValueUsd":100000000,"offeringPrice":9,"sharesOffered":10003889,"customDimensions":{"warrant_price":8.9999,"greenshoe_shares":1667250,"pre_funded_warrants":1111111}},"named_entities":{"people":[{"name":"Dana Cormack","role":"Corporate Communications"},{"name":"George E. MacDougall","role":"Investor Relations"}],"products":["RGX-202","ABBV-RGX-314","NAVSUNLI","RGX-121","RGX-111","ZOLGENSMA"],"companies":[{"name":"REGENXBIO Inc.","ticker":"RGNX"},{"name":"Morgan Stanley","relationship":"underwriter"},{"name":"J.P. Morgan","relationship":"underwriter"},{"name":"Leerink Partners","relationship":"underwriter"},{"name":"Mizuho","relationship":"underwriter"},{"name":"AbbVie","relationship":"partner"},{"name":"Nippon Shinyaku","relationship":"partner"},{"name":"Novartis","relationship":"partner"}],"dollarAmounts":[{"amount":"$9.00","context":"public offering price per share"},{"amount":"$8.9999","context":"pre-funded warrant price"},{"amount":"$100.0 million","context":"expected gross proceeds"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-17T11:06:37.352Z","global_importance":30,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap","eventGravity":"equity_offering","sectorWeight":"biotech"}},"durationMs":null,"modelName":"glm-4.7"}}